7 Hills Pharma has successfully dosed the first patient in a Phase 1b/2a clinical trial of Alintegimod, a first-in-class integrin-targeted agonist aimed at overcoming aPD-1-resistant solid tumors. This novel approach enhances T cell activation and immune cell trafficking, offering new hope for patients with difficult-to-treat cancers. Supported by CPRIT and the National Cancer Institute, this trial marks a significant advancement in cancer immunotherapy.

7 Hills Pharma has received a $13.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance 7HP349 (Alintegimod) into a Phase 1b/2a trial targeting PD-1-resistant solid tumors. This funding supports the development of a novel immunotherapy to overcome immune checkpoint inhibitor resistance, offering hope for checkpoint blockade-resistant patients.

7 Hills Pharma receives a $3 million SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop the first vaccine for Chagas disease. This innovative vaccine combination with 7HP349 aims to protect millions from the Trypanosoma cruzi parasite and prevent severe outcomes of the disease.

7 Hills Pharma announces the expansion of its patent portfolio with new claims covering innovative integrin agonist combination therapies. The newly issued patent no. 11,311,619 strengthens 7HP’s leadership in leveraging integrin activation to overcome immunotherapy resistance, expanding applications across diverse therapeutic areas.

7 Hills Pharma, in collaboration with MD Anderson and Texas Heart Institute, published a groundbreaking study in The Journal of Clinical Investigation showcasing how 7HP349 can convert "cold" melanoma tumors into "hot," T cell-enriched tumors, enhancing the efficacy of immune checkpoint blockade therapies. This novel approach offers a promising step forward in cancer immunotherapy.

Explore how LFA-1 activation with 7HP349 enhances T cell infiltration in cold tumors and synergizes with CTLA-4 blockade for improved cancer immunotherapy. Learn more about its impact on tumor immunity.

7 Hills Pharma announces that 7HP349, its lead oral immunostimulant, has been granted FDA Fast Track designation for use in combination with a CTLA-4 inhibitor for the treatment of anti-PD-1-resistant metastatic melanoma. This designation offers an expedited path for the development of 7HP349 in overcoming immunotherapy resistance in melanoma and other cancers.